Anavex Life Sciences Corp (AVXL)

[Investor2014]

A likely answer could be that the SAB members are aware of the extension data. Even if the data is not indisputably superior, but has promise, there may be enough incentive to join.

There are no doubt many biotechs with somewhat questionable data that still attract SAB members where they mutually see some chance of navigating towards a drug approval, which may ultimately fail, but allow for warrants or options to pay out along the way. However respectable a SAB member may be, it can of course be no guarantee of eventual drug approval.

Lastly, the extension data may in fact look out of this world hitherto unseen great. Just a matter of time before investors, traders, shorts, patients and the world at large get to know all for good reason that will become clear.

We have not seen negative news, we have had no news and share price bleeds. Rationally, if one was long yesterday because of the science, SAB and so, then it would also be rational to buy more stock at these prices?